Ankle osteoarthritis produces degenerative joint damage and persistent pain that may require structured pharmacological management. This protocol addresses first-line oral analgesic options where a structured, evidence-based approach to pain control is clinically warranted.
Patients with ankle osteoarthritis in whom a specific oral analgesic strategy is being considered — including those where the choice of agent is guided by tolerability and the availability of other viable options.
The evidence-based regimen involves consideration of a specific oral analgesic agent — including duloxetine, evaluated for osteoarthritis-related pain — alongside a distinct second oral option reserved for particular clinical circumstances. Full eligibility criteria, decision logic, and regimen details are in the complete protocol.
DOI: 10.1016/j.rdc.2022.03.009.
Though duloxetine is approved for OA in some countries, there were only conditional or weak recommendations for its use across all guidelines, reflecting general concerns about efficacy and tolerability.
Opioids, including tramadol, are generally not recommended, though guidelines did acknowledge that in some cases, such as in instances of contraindications, intolerance to, or inadequate response to NSAIDs, tramadol can be considered for pain relief in the absence of other viable options.
View source ↗